125 related articles for article (PubMed ID: 15197658)
1. Angiogenesis -- SMi conference.
Foley P
IDrugs; 2004 Jun; 7(6):551-3. PubMed ID: 15197658
[No Abstract] [Full Text] [Related]
2. Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better.
Usui-Ouchi A; Friedlander M
J Clin Invest; 2019 Jun; 129(8):3032-3034. PubMed ID: 31232702
[No Abstract] [Full Text] [Related]
3. Angiogenesis: novel and basic science insights and human therapy - keystone symposium.
Iruela-Arispe L
IDrugs; 2004 Feb; 7(2):111-3. PubMed ID: 15057650
[No Abstract] [Full Text] [Related]
4. Vascular endothelial growth factor pathway.
Krupitskaya Y; Wakelee H
J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1071-3. PubMed ID: 19861922
[No Abstract] [Full Text] [Related]
5. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer.
O'Reilly MS
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S64-6. PubMed ID: 17848299
[No Abstract] [Full Text] [Related]
6. A brief history of anti-VEGF for the treatment of ocular angiogenesis.
Kim LA; D'Amore PA
Am J Pathol; 2012 Aug; 181(2):376-9. PubMed ID: 22749677
[TBL] [Abstract][Full Text] [Related]
7. Retinal anti-angiogenesis by a new route.
Bicknell R
Nat Biotechnol; 2008 May; 26(5):528-9. PubMed ID: 18464784
[No Abstract] [Full Text] [Related]
8. Ten years of anti-vascular endothelial growth factor therapy.
Ferrara N; Adamis AP
Nat Rev Drug Discov; 2016 Jun; 15(6):385-403. PubMed ID: 26775688
[TBL] [Abstract][Full Text] [Related]
9. [Anti-angiogenesis treatment for brain tumors: present and future].
Takano S; Matsumura A
No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
[No Abstract] [Full Text] [Related]
10. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic agents in breast cancer.
Salter JT; Miller KD
Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
[No Abstract] [Full Text] [Related]
12. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
13. Fishing for a cure. Does the tiny zebrafish hold a key to stopping tumor growth?
Kiser K
Minn Med; 2005 Apr; 88(4):8-9. PubMed ID: 15940882
[No Abstract] [Full Text] [Related]
14. Vascular endothelial growth factor as a target for antiangiogenic therapy.
Gordon MS
J Clin Oncol; 2000 Nov; 18(21 Suppl):45S-6S. PubMed ID: 11060326
[No Abstract] [Full Text] [Related]
15. Antiangiogenic therapy and surgical practice.
John AR; Bramhall SR; Eggo MC
Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
[TBL] [Abstract][Full Text] [Related]
16. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason JO; Albert MA; Mays A; Vail R
Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
[No Abstract] [Full Text] [Related]
17. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.
Ye W
Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081
[TBL] [Abstract][Full Text] [Related]
18. Angiostasis-induced vascular normalization can improve photodynamic therapy.
Nowak-Sliwinska P; Wagnières G; van den Bergh H; Griffioen AW
Cell Mol Life Sci; 2010 May; 67(9):1559-60; author reply 1561. PubMed ID: 20155480
[No Abstract] [Full Text] [Related]
19. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
20. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
